Bortezomib in the treatment of AL amyloidosis: targeted therapy?
نویسندگان
چکیده
| 1302 | haematologica/the hematology journal | 2007; 92(10) Bortezomib in the treatment of AL amyloidosis: targeted therapy? Roberto Sitia, Giovanni Palladini, Giampaolo Merlini Department of Biology and Technology, DiBiT, Università Vita-Salute, San Raffaele Scientific Institute Milan, Italy (RS); Amyloid Center, Biotechnology Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Department of Biochemistry, University of Pavia, Italy (GP, GM). E-mail: [email protected]. DOI: 10.3324/haematol.12136
منابع مشابه
Brief Report CLINICAL TRIALS AND OBSERVATIONS A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
In amyloid light chain (AL) amyloidosis, clonal plasma cells use proteasomes to cope with misfolded light chain-induced proteotoxicity, and theproteasome inhibitor bortezomib is a potential targeted therapy. Early reports supported this expectation, showing high response rates, particularly upfront. A prospective trial showed that single-agent bortezomib ishighlyand rapidlyeffective.Combination...
متن کاملVentricular Fibrillation after Bortezomib Therapy in a Patient with Systemic Amyloidosis
A 64-year-old female was diagnosed with systemic amyloidosis associated with multiple myeloma. Bortezomib and dexamethasone-therapy was initiated; however, she developed lethal ventricular fibrillation (VF) and cardiac arrest after 84 hours of therapy. Cardiopulmonary resuscitation using direct current shocks with epinephrine and amiodarone was initiated but failed to receive cardiac function. ...
متن کاملTreatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Immunoglobulin light-chain (AL) amyloidosis is a clonal plasma cell dyscrasia. Delay in diagnosis is the major hurdle in improving the outcomes of AL patients. Almost all patients with systemic AL need cytotoxic therapy. Treatment can improve symptoms and quality of life, as well as extend survival. Supportive care is an integral part of the treatment plan. Severity of cardiac involvement is an...
متن کاملEfficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases. Patients received a median of 3 (range 1-6) cycles of bortezomib and 9 (45%) patients received concurrent dexamethasone. Three (15%) patients achieve...
متن کاملInduction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial
BACKGROUND Although the use of bortezomib alone and in combination with steroids has shown efficacy in AL amyloidosis, its role in combination with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) is unknown. In this study, we evaluated bortezomib in combination with dexamethasone (BD) for induction chemotherapy prior to HDM/SCT. METHODS This was a single-center, prospec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Haematologica
دوره 92 10 شماره
صفحات -
تاریخ انتشار 2007